Results 61 to 70 of about 125 (92)

Efficacy of targeted drugs for the treatment of adults with moderate-to-severe plaque psoriasis in the Russian Federation: a systematic literature review update

Фармакоэкономика, 2022
Background. A systematic literature review helps to identify the main treatment options, and evidence synthesis supports decision-making by comparing clinical efficacy of different treatments.
V. D. Sokolova, N. A. Sableva, V. V. Mladov, D. G. Tolkacheva   +3 more
doaj   +1 more source

Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy

Научно-практическая ревматология, 2023
Background. Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS).
A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova   +4 more
doaj   +1 more source

Evaluation of the efficacy and safety of an interleukin-17 inhibitor in hospitalized COVID-19 patients

Consilium Medicum
Aim. To evaluate the clinical efficacy and safety of netakimab (an interleukin-17 inhibitor) in hospitalized patients with severe COVID-19. Materials and methods. A retrospective case-control study was conducted involving 171 patients. The main group (
Zamira M. Merzhoeva, Andrey I. Yaroshetskiy, Natalya A. Tsareva, Natalia V. Trushenko, Galiya S. Nuralieva, Irina A. Mandel, Viliya V. Gaynitdinova, Sergey N. Avdeev   +7 more
doaj   +1 more source

Experience in managing psoriasis patients receiving targeted therapy during the COVID-19 pandemic

Медицинский совет, 2020
Introduction. With the onset of the COVID-19 pandemic the dermatological manifestations of the infection are widely discussed along with the correct management tactics for patients with severe chronic dermatoses, primarily those on immunosuppressive ...
N. N. Potekaev, O. V. Zhukova, S. I. Artemyeva, M. N. Ostretsova   +3 more
doaj   +1 more source

Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA

Современная ревматология
The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year ...
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, V. V. Tyrenko, E. A. Mikhailova, A. V. Eremeeva   +25 more
doaj   +1 more source

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis

ImmunoTargets and Therapy, 2021
Fabiola Atzeni,1 Antonio Carriero,2,3 Laura Boccassini,4 Salvatore D’Angelo2 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Rheumatology Institute of Lucania (IReL), Rheumatology ...
Atzeni F, Carriero A, Boccassini L, D'Angelo S   +3 more
doaj  

Efficacy, safety, and treatment persistence of netakimab in patients with active psoriatic arthritis in real-world clinical practice: interim results of the post-marketing safety study BCD-085-NIS-03/SIRIUS

Современная ревматология
Objective: to evaluate the efficacy, safety, and treatment persistence of netakimab (NTK) in patients with active psoriatic arthritis (PsA) in realworld clinical practice at 52 weeks of follow-up.Material and methods.
T. V. Korotaeva, O. A. Pritulo, O. B. Nesmeyanova, O. R. Ziganshin, L. L. Rusakova, E. S. Zhugrova, I. M. Marusenko, O. N. Mironenko   +7 more
doaj   +1 more source

Development of psoriasis during therapy with an interleukin-17 inhibitor in patients with ankylosing spondylitis: case reports and literature review

Современная ревматология
Paradoxical psoriasis (pPsO) is an exacerbation or de novo development of psoriasis (PsO) during treatment with drugs that are expected to control it. It is observed in approximately 5% of patients receiving tumor necrosis factor α inhibitors and less ...
Sh. F. Erdes, M. K. Kurbanmagomedov, M. M. Urumova   +2 more
doaj   +1 more source

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review

Frontiers in Pharmacology
Ankylosing spondylitis (AS) is a prototypical axial spondyloarthritis (axSpA) defined by chronic inflammatory back pain, progressive spinal stiffness, and frequent extra-articular manifestations such as acute anterior uveitis (21%–33%), inflammatory ...
Omar Z. Ameer, Reem Temsah, Yara O. Alsouss, Raghad Al-Amoudi, Mohammad A. Khanfar, Ibrahim M. Salman   +5 more
doaj   +1 more source

The Effect of Netakimab Therapy on the Life Quality of Patients with Plaque Psoriasis [PDF]

Effective Pharmacotherapy, 2019
A.S. Zhukov, V.R. Khairutdinov, A.V. Samtsov, R.A. Ivanov   +3 more
openaire   +1 more source